Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Amivantamab in EGFR or MET- Amplified Esophagogastric Cancer

NCT05117931 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT05117931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05117931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Amivantamab in EGFR or MET- Amplified Esophagogastric Cancer
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 2, 2021
Completion date
November 30, 2026
Enrollment
25 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

esophagogastric cancer